

Presentation of clinical data of SCO-240 at the 96th annual congress of Japan Endocrine Society: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders

Kanagawa, Japan, June 12, 2023 – SCOHIA presented the results of a phase 1 clinical trial for SCO-240, an orally bioavailable somatostatin receptor type 5 (SSTR5), at the 96th annual congress of Japan Endocrine Society.

Presentation title

SCO-240, a small molecule antagonist for somatostatin receptor type 5 (SSTR5), stimulates growth hormone secretion in humans

Please click [here](#) to view the presentation.

The binding of somatostatin to somatostatin receptors (SSTRs) regulates a diverse range of biological processes in mammals. However, the specific physiological role of SSTR5 in humans is largely unknown. In this phase 1 single-ascending-dose study, we evaluated the drug profile of SCO-240, an orally available selective SSTR5 antagonist, in healthy individuals. SCO-240 was generally safe and well tolerated at all evaluated doses (1–160 mg/man/day). Plasma concentrations of SCO-240 increased in a dose-dependent manner, and its plasma exposure remained consistent for 24 h, allowing a once-daily dosing. No clinically significant differences were observed in the pharmacokinetic profiles of SCO-240 between Japanese and Caucasian individuals or between fed and fasted conditions. Pharmacodynamic evaluation notably revealed that SCO-240 was highly effective at stimulating growth hormone (GH) secretion, without changing other pituitary hormone levels. This result represents the first evidence that a single dose of SCO-240 is safe and well tolerated and reveals that SCO-240-mediated antagonism of SSTR5 potentially stimulates GH secretion in humans. Therefore, SCO-240 may have therapeutic relevance in GH-related diseases.

SCOHIA is actively seeking a partner worldwide for the further development and commercialization of SCO-240.

About SCOHIA PHARMA, Inc.:

SCOHIA PHARMA, Inc. is a drug discovery company focusing on the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases where high unmet medical needs still remain. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit <https://www.scohia.com/eng/>.

Investor Relations and Media

SCOHIA PHARMA:

Corporate Communication

info@scohia.com